Regional EPO Deals: Large vs. Small Molecules

Two recent deals in the EPO space by Astellas and Takeda show how Japanese pharma is competing at top level for product rights outside its domestic market, and illustrate the heady terms that next-generation EPO candidates command. They're also another sign that regional dealmaking is back.

It seems that Astellas Pharma Inc. 's jaw-dropping $300 million up-front payment for ex-US rights to FibroGen Inc. 's Phase II anemia compounds hasn't, after all, forced a recalibration of deal terms in the EPO space. [See Deal] (See "FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug," IN VIVO, June 2006 Also see "FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug" - In Vivo, 1 June, 2006..) A month later, compatriot Takeda Pharmaceutical Co. Ltd. parted with an up front just one third as large, and pre-approval milestones worth just 60% of those in the FibroGen/Astellas deal, to expand its rights beyond Japan to a Phase II anemia drug of its own, Affymax Inc. 's erythropoiesis stimulating agent Hematide. [See Deal]

The two deals are worth a closer look, though, both for their similarities, and their differences. (See Exhibit 2.)

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.